Population Pharmacokinetics of Encorafenib and Binimetinib in Real-World BRAFV600E/K-Mutant Metastatic Melanoma Patients in Comparison with Clinical Results

preprint OA: closed
Full text JSON View at publisher
AI-generated deep summary by claude@2026-07, 2026-07-04 · read from full text

This preprint studied the population pharmacokinetics of encorafenib and binimetinib in real-world patients with BRAF V600E/K-mutant metastatic melanoma, using routine therapeutic drug monitoring data to model interindividual variability and assess potential covariates affecting drug exposure. Population PK analyses of plasma concentration–time data from 66 encorafenib-treated and 69 binimetinib-treated patients found that a two-compartment model with first-order absorption and linear elimination best described concentrations, with improved performance when interindividual variability was included on clearance (and additional parameters for encorafenib). No clinically relevant covariate was reported to impact PK parameters, and model-predicted exposure metrics (trough, peak, half-life, and AUC) were comparable to clinical trial values, while the authors note the ongoing lack of robust PK/pharmacodynamic evidence for optimal TDM. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Aim: : Despite their recent approval, encorafenib and binimetinib pharmacokinetic (PK) studies in real-world cancer patients remain scarce. We aimed to characterize their population pharmacokinetics (popPK) in routine care clinical care and compare real-life exposure metrics with clinical trial data. Methods: : We conducted population pharmacokinetic (popPK) analyses in real-life patients with BRAF V600E/K -mutant metastatic melanoma to characterize interindividual variability (IIV) and identify potential covariates susceptible to influence the drugs PK. These models allowed the comparison between patients PK metrics (i.e., trough concentration, C min , maximal concentration, C max , and area under the curve, AUC τ ) with data from clinical trials. Results: : Encorafenib and binimetinib data were available from 66 and 69 patients, respectively, providing 310 and 311 plasma concentrations collected during routine therapeutic drug monitoring (TDM). For both drugs, a two-compartment model with first-order absorption and linear elimination best described the concentration–time data. Including IIV on clearance and intercompartmental clearance, and, for encorafenib, on the peripheral volume of distribution, significantly improved model performance. No clinically relevant covariate impacted the PK parameters. Model-predicted PK metrics (geometric mean and CV(%)) for encorafenib and binimetinib in our real-life population were: C min 19 ng/mL (73%) and 55 ng/mL (56%), C max 3378 ng/mL (30%) and 367 ng/mL (24%), and half-lives 12.5 h (95%) and 7.3 h (67%), respectively. Encorafenib AUC 24h was 15785 ng·h/mL (17%) and binimetinib AUC 12h was 2003 ng·h/mL (22%). Conclusion: : Overall, these metrics are comparable to those reported in clinical trial data; yet the absence of robust PK/pharmacodynamic evidence continues to challenge optimal TDM.
Full text 8,540 characters · extracted from preprint-html · click to expand
Population Pharmacokinetics of Encorafenib and Binimetinib in Real-World BRAFV600E/K-Mutant Metastatic Melanoma Patients in Comparison with Clinical Results | Authorea try { document.documentElement.classList.add('js'); } catch (e) { } var _gaq = _gaq || []; _gaq.push(['_setAccount', 'G-8VDV14Y67G']); _gaq.push(['_trackPageview']); (function() { var ga = document.createElement('script'); ga.type = 'text/javascript'; ga.async = true; ga.src = ('https:' == document.location.protocol ? 'https://ssl' : 'http://www') + '.google-analytics.com/ga.js'; var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(ga, s); })(); Skip to main content Preprints Collections Wiley Open Research IET Open Research Ecological Society of Japan All Collections About About Authorea FAQs Contact Us Quick Search anywhere Search for preprint articles, keywords, etc. Search Search ADVANCED SEARCH SCROLL This is a preprint and has not been peer reviewed. Data may be preliminary. 11 September 2025 V1 Latest version Share on Population Pharmacokinetics of Encorafenib and Binimetinib in Real-World BRAFV600E/K-Mutant Metastatic Melanoma Patients in Comparison with Clinical Results Authors : Yuan J. Pétermann , Alicja Puszkiel , Abbas Khani , Nora Kramkimel , Elisa Funck-Brentano , Benédicte Oules , Sarah Bouchereau , Michel Vidal , Xavier DECLEVES , Chantal Csajka , Benoit Blanchet , and Monia Guidi 0000-0002-6419-9317 [email protected] Authors Info & Affiliations https://doi.org/10.22541/au.175758519.96583383/v1 216 views 111 downloads Contents Abstract Supplementary Material Information & Authors Metrics & Citations View Options References Figures Tables Media Share Abstract Aim : Despite their recent approval, encorafenib and binimetinib pharmacokinetic (PK) studies in real-world cancer patients remain scarce. We aimed to characterize their population pharmacokinetics (popPK) in routine care clinical care and compare real-life exposure metrics with clinical trial data. Methods : We conducted population pharmacokinetic (popPK) analyses in real-life patients with BRAF V600E/K -mutant metastatic melanoma to characterize interindividual variability (IIV) and identify potential covariates susceptible to influence the drugs PK. These models allowed the comparison between patients PK metrics (i.e., trough concentration, C min , maximal concentration, C max , and area under the curve, AUC τ ) with data from clinical trials. Results : Encorafenib and binimetinib data were available from 66 and 69 patients, respectively, providing 310 and 311 plasma concentrations collected during routine therapeutic drug monitoring (TDM). For both drugs, a two-compartment model with first-order absorption and linear elimination best described the concentration–time data. Including IIV on clearance and intercompartmental clearance, and, for encorafenib, on the peripheral volume of distribution, significantly improved model performance. No clinically relevant covariate impacted the PK parameters. Model-predicted PK metrics (geometric mean and CV(%)) for encorafenib and binimetinib in our real-life population were: C min 19 ng/mL (73%) and 55 ng/mL (56%), C max 3378 ng/mL (30%) and 367 ng/mL (24%), and half-lives 12.5 h (95%) and 7.3 h (67%), respectively. Encorafenib AUC 24h was 15785 ng·h/mL (17%) and binimetinib AUC 12h was 2003 ng·h/mL (22%). Conclusion : Overall, these metrics are comparable to those reported in clinical trial data; yet the absence of robust PK/pharmacodynamic evidence continues to challenge optimal TDM. Supplementary Material File (20250903_binimetinib_encorafenib_poppk_bjcp.docx) Download 2.17 MB Information & Authors Information Version history V1 Version 1 11 September 2025 Copyright This work is licensed under a Non Exclusive No Reuse License. Authors Affiliations Yuan J. Pétermann Centre Hospitalier Universitaire Vaudois View all articles by this author Alicja Puszkiel Assistance Publique - Hopitaux de Paris View all articles by this author Abbas Khani Centre Hospitalier Universitaire Vaudois View all articles by this author Nora Kramkimel Assistance Publique - Hopitaux de Paris View all articles by this author Elisa Funck-Brentano Hopital Ambroise-Pare View all articles by this author Benédicte Oules Assistance Publique - Hopitaux de Paris View all articles by this author Sarah Bouchereau Hopital Ambroise-Pare View all articles by this author Michel Vidal Assistance Publique - Hopitaux de Paris View all articles by this author Xavier DECLEVES Assistance Publique - Hopitaux de Paris View all articles by this author Chantal Csajka Centre Hospitalier Universitaire Vaudois View all articles by this author Benoit Blanchet Assistance Publique - Hopitaux de Paris View all articles by this author Monia Guidi 0000-0002-6419-9317 [email protected] Centre Hospitalier Universitaire Vaudois View all articles by this author Metrics & Citations Metrics Article Usage 216 views 111 downloads .FvxKWukQNSOunydq8rnd { width: 100px; } Citations Download citation Yuan J. Pétermann, Alicja Puszkiel, Abbas Khani, et al. Population Pharmacokinetics of Encorafenib and Binimetinib in Real-World BRAFV600E/K-Mutant Metastatic Melanoma Patients in Comparison with Clinical Results. Authorea . 11 September 2025. DOI: https://doi.org/10.22541/au.175758519.96583383/v1 If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download. For more information or tips please see 'Downloading to a citation manager' in the Help menu . Format Please select one from the list RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks Direct import Tips for downloading citations document.getElementById('citMgrHelpLink').addEventListener('click', function() { popupHelp(this.href); return false; }); $(".js__slcInclude").on("change", function(e){ if ($(this).val() == 'refworks') $('#direct').prop("checked", false); $('#direct').prop("disabled", ($(this).val() == 'refworks')); }); Cited by Hamza Sayadi, Yeleen Fromage, Marc Labriffe, Caroline Monchaud, Héloïse Jourdain, Hélène Géniaux, Jean-Baptiste Woillard, From empirical caution to precision resumption: model-informed management of a binimetinib overdose in a frail elderly patient, European Journal of Clinical Pharmacology, 82 , 4, (2026). https://doi.org/10.1007/s00228-026-04040-8 Crossref Loading... View Options View options PDF View PDF Figures Tables Media Share Share Share article link Copy Link Copied! Copying failed. Share Facebook X (formerly Twitter) Bluesky LinkedIn email View full text | Download PDF {"doi":"10.22541/au.175758519.96583383/v1","type":"Article"} Now Reading: Share Figures Tables Close figure viewer Back to article Figure title goes here Change zoom level Go to figure location within the article Download figure Toggle share panel Toggle share panel Share Toggle information panel Toggle information panel Go to previous graphic Go to next graphic Go to previous table Go to next table All figures All tables View all material View all material xrefBack.goTo xrefBack.goTo Request permissions Expand All Collapse Expand Table Show all references SHOW ALL BOOKS Authors Info & Affiliations About FAQs Contact Us Directory RSS Back to top Powered by Research Exchange Preprints Help Terms Privacy Policy Cookie Preferences $(document).ready(() => setTimeout(() => { let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" ")); $.get("/resource/lodash?t="+_bnt); },4000)); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'a00714452e698650',t:'MTc3OTU3MDk2MA=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00